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Objectives. The aim of this study was to characterize cardiac
sympathetic nervous function in patients with severe heart failure
and to Investigate the Influence of the cause of heart failure,
heal udynamic variables and central nervous system catech trine
rely use on cardiac sympathetic tone .
Backgmmnd. Although head failure is generally accompanied
by symp,%thoexcitation, the integrity of cardiac sympathetic nerve
fuadion in hod failure remains controversial, particularly in
relstflon to nerve firing activity and to the capacity of sympathetic
nerves to recapture pore pinephrive . Additionally, the location of
the affirrent and central neural pathways implicated in heart
failure-Induced sympathoexcitation remains unclear.
Whodh InulkArv,er techniques were applied in 41 patients
with severe head failure and IS healthy control subjects to study
the biochemical aspects of whole body and cardiac sympathetic
activity. Hemodynamic Indexes of cardiac performance were
measured In the heart failure group, and their association with
sympathetic activity was studied . Jugular venous catechol spill-
over was Inessured to study the central noudrenergle control of
sympathetic outflow .
The development of congestive heart failure is accompanied
by activation of a variety of neural and hormonal counter-
regulatory systems. These include the sympathetic nervous
system (1-4) and the renin-angiotensin-aldosterone axis (5-
7), with accompanying increased release of vasopressin (8)
and endothelin (9).
Evidence for activation of the sympathetic nervous sys-
tem in heart failure includes increased plasma norepineph-
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Results. Sympathoexcitation was evident in the heart failure
group, reflected by a 62% increase (p < 0 .001) in total body and
a 277% increase (p < 0 .001) in cardiac norepinephrine spillover
rates . These changes were accompanied by significant increases in
the cardiac .;pillover of the norepinephrine precursor dihydroxy-
phenylalanine, the sympathetic cotransmitter neuropeptide Y and
the extra neuronal metabolite 3-methoxy4 .hydroxyphenylglycol.
The level of cardiac sympathetic activity was significantly corre-
lated (r = 0.59, p < 0.001) with the mean pulmonary artery
pressure . An increase in the spillover of dihydroxyphenylainnine
and 3-metboxy-4-hydroxyphenylglycol from the brain was
present, suggesting activation of central noradrenergic neurons .
Conclusions. Cardiac sympathetic activation is present in
severe heart failure, bearing a close relation with pulmonary
artery pressures, independent of heart failure etiology . Activation
of noradrenergic neurons in the brain is also present and may be
the underlying central nervous mechanism of the sympathoexci-
tallon Oserved in heart failure .
(J Am Coll Cardiol 1994,23 .570-8)
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rine (1), elevated norepinephrine spillover to plasma as
measured by the isotope-dilution technique (2) and increased
sympathetic nerve discharge rates in skeletal muscle (3) .
Although "overall" sympathoexcitation is generally ob-
served in clinically apparent heart failure, considerable
variation in sympathetic outflow to various vascular beds
exists (2) . Cardiac sympathetic nervous activity has been
assessed in this condition by measuring either venoarterial
norepinephrine gradients (4,10) or norepinephrine spillover
(2) and appears to be the site where sympathoexcitation is
most prominent. Despite general agreement that activation
of cardiac sympathetic nerves occurs in heart failure, its
degree remains controversial, largely because of conflicting
reports that describe normal (11) or reduced (4) reuptake of
norepinephrine in heart failure . An assessment of norepi-
nephrine reuptake is of particular importance in the mea-
surement of regional sympathetic activity because faulty
recapture would cause increased norepinephrine overflow
from the heart to plasma for a given rate of sympathetic
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nerve firing, perhaps giving rise to an overestimation of the
extent of neural activation .
The physiologic implications of these obser\ ations, how-
ever, remain somewhat unclear when sympathetically medi-
ated neuroeffector responses are attenuated in heart failure .
perhaps attributable to downregulation of beta-adrenocep-
tors or abnormalities of G proteins (12,13) . In contrast,
chronic high levels of norepinephrine as present in heart
failure may exert cardiotoxic actions (14) and play a facili-
tative role in the genesis of ventricular arrhythmias (15) .
Accordingly, a more complete understanding of the cardiac
sympathetic profile of patients with heart failure would have
implications for devising optimal treatment strategies .
Although a detailed understanding of the mechanisms
that integrate afferent hemodynamic signals, central process-
ing and efferent neural outflow for arterial blood pressure
control has emerged (16,17), in heart failure the afferent
stimulus for chronic overall and cardiac sympathetic activa-
tion remains largely unknown (18) . Leimbach et al. (3) have
observed a significant positive correlation between left ven-
tricular filling pressures and muscle sympathetic nervous
activity, perhaps suggesting a role for cardiopulmonary
baroreceptors . Additionally, it is unclear whether the periph-
eral sympathoexcitation that occurs in heart failure is driven
by activation of central neural controlling processes, similar
to those in the brainstem that participate in arterial blood
pressure control .
To resolve these insufficiently clarified issues of cardiac
sympathetic function in heart failure, we studied a large
cohort of patients with severe heart failure (of various
etiologies) by examining the spillover from the heart to
plasma of the sympathetic neurotransmitter norepinephrine,
its precursor and metabolites and that of the sympathetic
cotransmitter neuropeptide Y . To examine the central con-
trolling processes of cardiac sympathetic activity in heart
failure, we measured the overflow of norepinephrine and
related catechols (dihydroxyphenylalanine, dihydroxyphe-
nylglycol and 3-methoxy-4-hydroxyphenylglycol) from the
brain because of the important contribution of central mono-
aminergic neurons to the control of sympathetic nervous
outflow. Further, we explored the relation between sympa-
thetic activity and hemodynarnic indexes that might repre-
sent afferent inputs to the central nervous system .
Methods
Study patients . The study group comprised 41 patients
with severe heart failure (age 51 1 years) and 15 healthy
volunteers (age 46 ± 5 years, p NS). The patients with
heart failure were all in New York Heart Association func-
tional class III or IV (averag, ; left ventricular ejection
fraction determined by radionuclide ventriculography 18 .5 ±
1.1%) and were undergoing assessment for suitability z
candidates for heart transplantation . Of these patients, 20
had ischemic cardiomyopathy (demonstrated angiographi-
cally) and the 21 remaining patients in the nonischemic group
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included 15 patients with idiopathic dilated cardiomyopathy,
2 with alcoholic cardiomyopathy and I patient each with
heart failure due to hypertension, valvular heart disease,
doxorubicin toxicity or restrictive cardiomyopathy. In all
cases, the patient's heart failure was considered to be of
such severity that discontinuation of medications was not
appropriate. Medications were generally comparable in all
patients and included furosemide (98%), an angiotensin-
converting enzyme inhibitor (98%) and warfarin . Thirty-four
patients were receiving digoxin, whereas the remaining
seven had not received digoxin for > l month . The healthy
control subjects were recruited by advertisement in the
general community . The study was performed with the
approval of the Alfred Hospital Ethics Review Committee
and all subjects gave written informed consent .
Catheterization protocol . All studies were performed in
the morning after a light breakfast . All subjects had refrained
from smoking and from consuming caffeinated beverages
over the 12 h before the procedure . Under local anesthesia,
the radial artery was camuWed (3F, 5 cm, Cook) for arterial
pressure monitoring and blood sampling . In the healthy
volunteers, a venous introducer sheath was placed in the
antecubital fossa . In the patients with heart failure, the
sheath was placed in either the antecubital fossa or the right
internal jugular vein .
In the patients with heart failure, a pulmonary artery
thermodilution catheter (7F, Arrow, Arrow International)
was advanced to the pulmonary circulation for the measure-
ment of right heart pressures, pulmonary capillary wedge
pressure and cardiac output. Subsequently in these patients
and the healthy control subjects, a coronary sinus thermodi-
lution catheter (Webster CCS 7/8U 90A, Webster Laborato-
ries) was positioned in the coronary sinus under fluoroscopic
control for blood sampling and determination of coronary
sinus blood flow (19) . In I I patients with heart failure and 14
healthy control subjects, the coronary sinus catheter was
also manipulated into the right internal jugular vein above
the confluence of the facial veins for thermodilution mea-
surement of jugular venous blood flow and blood sampling
for the determination of plasma catecholamines in the ve-
nous effluent from the brain .
Neurochemical measures of sympathetic activity. Whole
body sympathetic activity . The norepinephrine isotope-
dilution technique as previously described by this laboratory
(20,21) was employed to provide a biochemical index of
"global" sympathetic nerve activity . In brief, tritiated levo-
(7_
3
H)-porepinephrine (New England Nuclear) was infused
continuously at a rate of 0 .5 to I 1ACilmin through a periph-
eral vein for Y60 min to achieve steady-state plasma con-
centrations. Once steady-state conditions had been
achieved, the total norepinephrine spillover to plasma and
norepinephrine plasma clearance were calculated as previ-
ously described (20) .
Cardiac sympathetic activity . An
extensive neurochem-
ical assessment of cardiac sympathetic nerve function was
performed by measuring the transcardiac spillover of nor-
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epinephrine, its precursor dihydroxyphenylalanine, the in-
traneuronal metabolite of norepinephrine dihydroxyphenyl-
glycol and an extraneuronal metabolite of norepinephrine,
3-methoxy-4-hydroxyphenylglycol . Additionally, the car-
diac release of neuropeptide Y, which is coreleased with
norepinephrine from intraneuronal vesicular stores (22-24),
was also measured as a further guide to cardiac sympathetic
nervous activity . The regional spillover of norepinephrine
from the heart was determined by using the modified Fick
principle, which relies on a correction for the fractional
extraction of tritiated norepinephrine across the vascular
bed concerned (21,25) . The spillover of neuropeptide Y and
dihydroxyphenylalanine was determined by calculating the
product of their respective venoarterial concentration gradi-
ents and the coronary sinus plasma flow, whereas dihydroxy-
phenylglycol spillover was computed by using coronary
sinus blood flow because this lipophilic catechol is evenly
distributed between plasma and red blood cells (26) . Release
of 3-methoxy-4-hydroxyphenylglycol across the heart was
determined in the same manner (for 25 patients with heart
failure and 9 control subjects) used to determine the dihy-
droxyphenylglycol spillover, on the basis of preliminary
observations from our laboratory suggesting that 3-methoxy-
4-hydroxyphenylglycol is also evenly distributed between
plasma and red blood cells .
Central nervous cater minergic activity. On the basis
of an extensive body of experimental evidence (27-30)
suggesting that noradrenergic nuclei in the forebrain play an
important stimulant role in regulating sympathetic nervous
outflow, we used radiotracer methods to test for the pres-
ence of increased central noradrenergic activity in patients
with heart failure . Recent clinical research (31) supports the
application of this approach to assessing central noradrener-
gic activity by demonstrating the existence of a direct
relation between norepincphrine release from the brain and
peripheral sympathetic nervous activity . The turnover of
norepinephrine in the central nervous system was assessed
indirectly by measuring the rate of spillover of norepineph-
rine and the related catechols dihydroxyphenylalanine, di-
hydroxyphenylglycol and 3-methoxy-4-hydroxyphenylgly-
col into an internal jugular vein (25,32) . The tip of the
coronary sinus thermodilution catheter was placed beyond
the mandibular angle, proximal to the entry of any facial
veins, to minimize the contamination of the cerebral venous
effluent . The catheter was used for sampling jugular venous
blood and for blood flow determination by the thermodilu-
tion technique (32) . The spillover of norepinephrine, dihy-
droxyphenylalanine, dihydroxyphenylglycol and 3-methoxy-
4-hydroxyphenylglycol was calculated according to those
methods used to determine their spillover from the heart .
B mica) assays. Blood samples were collected into
ice-chilled tubes containing an anticoagulant, ethylenegly-
col-bis ($-amino-ethyl ether) N,N° tetraacetic acid (EGTA)
and reduced glutathione to prevent oxidation . After centrif-
ugation, plasma samples were stored at -80°C until assayed .
Norepinephrine, dihydroxyphenylalanine and dihydroxy-
phenylglycol concentrations were determined by high per-
formance liquid chromatography with electrochemical de-
tection as previously described (33) . The plasma-specific
activity of tritiated norepinephrine and dihydroxyphenylgly-
col was determined by liquid scintillation spectroscopy after
fractional collection of the eluant from the electrochemical
detector cell . Plasma concentrations of 3-methoxy-4-
hydroxyphenylglycol were determined using a technique
adapted from Eisenhofer et al . (34) . In brief, 3-methoxy-4-
hydroxyphenylglycol was extracted from ultrafiltered
plasma samples by the addition of ethyl acetate, followed by
drying under nitrogen . 3-methoxy-4-hydroxyphenylglycol
was then reconstituted and underwent liquid chromatogra-
phy with electrochemical detection . Plasma neuropeptide Y
levels were determined by direct immunoassay using anti-
serum raised in rabbits immunized with synthetic neuropep-
tide Y as previously described (23,35) .
Statistical methods . Data are presented as mean value ±
SEM. Where normally distributed, group data were com-
pared using an unpaired Student t test. Data showing non-
normal distribution were compared using the Mann-Whitney
U test. Relations between continuous variables were exam-
ined using the least squares method of linear regression .
Variables that were significantly related to the cardiac nor-
epinephrine spillover rate in a univariate analysis were
entered into a stepwise multivariate analysis (SPSS-PC) to
detect the independent variables that were significantly
related to the cardiac norepinephrine spillover rate . These
included the mean pulmonary artery pressure, left ventricu-
lar ejection fraction, mean arterial blood pressure and car-
diac output . The pulmonary capillary wedge pressure was
not entered because of a significant relation (r = 0 .93, p <
0.001) with the mean pulmonary artery pressure . The criteria
were p < 0 .05 for entry and p < 0 .10 for removal . Analysis
of covariance was used to compare the slopes and intercepts
of the relation for two continuous variables between groups,
according to previously described methods (36) . The null
hypothesis was rejected where the p value was < 0.05 .
Results
Hemodynamic profiles . Patients with congestive heart
failure demonstrated a significantly abnormal hemodynamic
profile consistent with the severity of their heart failure. The
pulmonary capillary wedge pressure was 21 .5 ± 1 .3 mm Hg,
mean pulmonary artery pressure 29 .7 ± 1 .6 mm Hg and
cardiac output was 3 .9 ± 0.1 liters/min. The mean arterial
blood pressure in the patients with heart failure was 79 .4 ±
1 .7 mm Hg compared with 96.1 ± 1 .8 mm Hg in the control
subjects (p < 0 .001). In the patients with heart failure,
coronary sinus blood flow tended to be higher (212 ±
15 ml/min) than that in control subjects (168 ± 17 ml/min)
(p = 0.06 [NS]) . The thermodilution-derived unilateral inter-
nal jugular venous blood flow was not significantly different
between patients with heart failure (409 ± 68 mUmin, n = 11)
and control subjects (446 ± 46 ml/min, n = 14). When
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Table 1 . Neurochemical Profile of Severe Heart Failure
*p < 0 .001 . Q < 0
.01
. Q < 0
.05
. DHPG = dihydroxyphenylglycol ;
DOPA = dihydroxyphenylalanine ; MHPG = 3-methoxy-4-hydroxyphenylgly-
col, NE = norepinephrine ; NPY = neuropeptide Y ; SR = spillover rate .
examined by etiology of heart failure, the henlodynamic
profiles of the patients with ischemic k;ardiomyopaahy
closely resembled those of patients with heart failure of
nonischemic origin, only the cardiac output differing signif-
icantly (ischemic vs . nonischemic etiology (3 .7 ± 0 .2 vs .
4.2 ± 0 .2 liters/min, p < 0.05). The coronary sinus blood
flow was not significantly different in these two groups (196 ±
24 vs. 227 ± 20 Knin), although it tended to be lower in those
of patients with an ischemic etiology of heart failure .
Neurochemical measures of whole body and cardiac sym-
pathetic activity. The arterial concentration of norepineph-
rine was significantly increased in patients with heart failure
(3,296 ± 242 vs . 1,397 ± 165 pmol/liter, p < 0.001). In
patients with heart failure, the whole body spillover rate of
norepinephrine was increased by 62% (5,448 ± 363 vs .
3,354 ± 355 pmoUrnin, p < 0 .001) and the rate of clearance
of norepinephrine from plasma was significantly reduced by
28% (1 .74 ± 0.08 vs . 2.51 ± 0.16 liters/min, p < 0 .001) .
Patients with heart failure had a 277% increase in the rate
of norepinephrine spillover to plasma from the heart com-
pared with values in control subjects (394 ± 46 vs .
105 ± 19 pmol/min, p < 0 .001). There was an accompanying
significant increase in the cardiac release of dihydroxyphe-
nylalanine, tritiated dihydroxyphenylglycol (the tritiated in-
traneuronal norepinephrine metabolite) and 3-methoxy-4-
hydroxyphenylglycol (the extraneuronal metabolite of
norepinephrine), consistent with increased cardiac sympa-
thetic nervous activity (Table 1). The fractional extraction of
tritiated norepinephrine across the heart was significantly
depressed in subjects with heart failure (0 .56 ± 0.02 vs .
0.78 ± 0.04, p < 0.001). The concentration of neuropeptide
Y (which is coreleased with norepinephrine from sympa-
thetic nerve terminals) in arterial plasma was modestly
elevated in the patients with heart failure (273 ± 38 vs . 187 ±
29 pg/ml, p = 0 .07). However, cardiac release of neuro-
peptide Y was significantly elevated compared with that
in control subjects, in whom net extraction was evident
(Table 1).
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Figure 1 . Bar graphs comparing cardiac spillover (SR) of norepineph-
rine
(NE),
dihydroxyphenylalanine (DOPA), dihydroxyphenylglycol
(DHPG), 3 nethoxy-4-hydroxyphenylglycol (MHPG), tritiated DHPG
(3H DHPG) and the extraction of tritiated norepinephrine from plasma
across the heart in ischemic (open bar) and nonischemic (solid bar)
cardiomyopathy .
Influence of cause of heart failure and therapy on sympa-
thetic activity . To examine the effect of potential influences
of etiology on cardiac sympathetic nervous function, we
compared the variables of cardiac sympathetic neural integ-
rity among patients with failure of ischemic and nonischemic
background (Fig . 1). The spillover of norepinephrine into
plasma across the heart was similar in patients with ischemic
(348 ± 57 pfnoUmin) and nonischc .-aic (438 ± 71 pmol/min)
heart failure. The fractional extraction of tracer norepineph-
rine across the heart was also similar in patients with
ischemic and nonischemic heart failure . The production of
the related catechols, dihydroxyphenylalanine, dihydroxy-
phenylglycol and 3-methoxy-4-hydroxyphenylglycol was
also similar (Fig . 1). Although the cardiac production of
tritiated dihydroxyphenylglycol was not significantly differ-
ent, a trend toward higher production was present in the
nonischemic group . Because the ischemic heart failure co-
hort had a significantly lower cardiac output and a tendency
toward a lower left ventricular ejection fraction than that of
patients with idiopathic cardiomyopathy, we used an analy-
sis of covariance to compare the cardiac production of
norepinephrine and tritiated dihydroxyphenylglycol with the
15000
12500
5000
2500
Control
Subjects
Patients with
Heart Failure
Arterial NE (pmol/Iiter) 1,397 165 3,296 ± 242*
Total NE SR (pmolimia) 3,354 355 5,448 ± 363*
Total NE clearance (liters/min) 2 .51 0 .16 1 .74 ± 0 .08*
Cardiac NE SR (pmollmin) 105 19 394 ± 46*
Cardiac tritiated NE extraction 0.78 0 .04 0.56 ± 0 .02*
Cardiac DOPA SR (pmollmin) 110 ± 9 201
t
29$
Cardiac DHPG SR (pmollmin) 682 ± 86
659 ± 79
Cardiac tritiated DHPG SR (dpm/min) 3,928 ± 685 7,472 ± 1,043t
Cardiac MHPG SR (pmol/min) 252 ± 73 564 ± 78f
Cardiac NPY SR (pg/min)
-834 ± 926 1,759 ± 786+
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cardiac output as a covariate . In this analysis, the cause of
heart failure was further demonstrated not to be of signifi-
cance in determining the rate of norepinephrine spillover
from the heart .
Although the medications prescribed were very similar
among the patients with heart failure, 7 of the 41 patients
were not receiving digoxin
. Because of this difference and
previous suggestions that digoxin might influence sympa-
thetic nervous function (37-39), we compared the neuro-
chemical profiles of patients with heart failure according to
the presence or absence of digoxin therapy. The hemody-
namic profile of those subjects
treated with digoxin was not
significantly different from that of patients not receiving
cardiac glycosides. Furthermore, the arterial norepinephrine
concentration (3,292 ± 281 vs
. 3,310 ± 434 pmol/liter) and
the whole body spillover rate for norepinephrine (5,505 ±
410 vs
. 5,138 ± 735 pmollmin) were similar in those patients
receiving digoxin and those not . In the heart, the fractional
extraction of norepinephrine across the heart was not
different according to the presence (0 .55 0.03) or absence
(0.57 ± 0.03) of digoxin therapy . Although the spillover of
norepinephrine from the heart was not significantly influ-
enced by digoxin treatment, there were trends toward higher
spillover rates for norepinephrine and related catechols in
those patients not receiving digoxin . These trends could not
be further resolved by analysis of covariance with either the
pulmonary arterial pressures or cardiac output as the cova-
riate.
H yn is correlates of sympathetic activity. Consis-
tent with a possible underlying reflex mechanism for the
significant increase in cardiac sympathetic activity in the
setting of heart failure, there was a modest significant
positive univariate correlation (Fig . 2) of cardiac norepi-
nephrine spillover with both the mean pulmonary artery
pressure (r = 0.59, p < 0.001) and the pulmonary capillary
w pressure (r = 0.50, p < 0.01). In addition, there was
a weaker negative correlation with cardiac output (r
-0.32, p < 0.05). Stepwise multiple regression analysis
identified the mean pulmonary artery pressure as the only
he ynamic factor that contributed significantly to a re-
gression model of the cardiac norepinephrine spillover rate .
Cardiac production of tritiated dihydroxyphenylglycol and
dihydroxyphenylalanine (r = 0 .48, p < 0.01 and r = 0 .35,
p < 0.05) was also significantly related to both the pulmo-
nary artery pressure and wedge pressure . Of note, there was
no demonstrable relation between the mean arterial pressure
and cardiac norepinephrine spillover, whereas the whole
body norepinephrine spillover was weakly negatively corre-
lated with systemic arterial pressure (r = -0 .36, p < 0.05) .
Left ventricular ejection fraction had no relation with mea-
surements of either cardiac or whole body sympathetic
activity.
Cea nervous cater rgic activity. We examined
the spillover of norepinephrine and related lipophilic cate-
chols from the brain in 11 patients with heart failure and 14
control subjects
. The spillover of norepinephrine into the
50
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F 1'e 2 . Scatterplots showing the relationship between cardiac
norepinephrine (NE) spillover and mean pulmonary artery pressure
(PA), pulmonary capillary wedge pressure (Pulm Wedge) and car-
diac output . L = liters .
cerebrovascular circulation was not significantly different in
the heart failure (112 ± 34 pmol/min) and control (93 ±
61 pmol/min) groups (Fig . 3). However, the spillover of
dihydroxyphenylalanine was significantly elevated in pa-
tients with heart failure (558 ± 118 pmollmin vs . 173 ±
94 pmollmin, p < 0.05). In conjunction with this finding, the
spillover of endogenous dihydroxyphenylglycol (404 ± 110
vs. 192 ± 76 pmollmin) and labeled dihydroxyphenylglycol
(3,362 t 1,931 vs . 1,182 = 648 dpm/min) showed a trend
toward higher levels in patients with heart failure (p = NS) .
The spillover of the extraneuronal norepinephrine metabolite
3-methoxy-4-hydroxyphenylglycol into the cerebral circulation
was significantly elevated in patients with heart failure (2,369 ±
577 vs. 789 ± 146 pmollmin, p = 0.02 [Fig. 3]) .
Discussion
In the current study, we examined the whole body
sympathetic, cardiac sympathetic and central catecholamin-
JACC Vol . 23, No . 3
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Figure 3 . Spillover of norepinephrine (NE), dihydroxyphenylaia-
nine (DOPA), dihydroxyphenylglycol (DHPG) and 3-methoxy-4-
hydroxyphenylglycol (MHPG) into the jugular vein in normal
subjects (open bar) and patients with heart failure (solid bar) . *p <
OAS .
ergic neurochemical profile of patients with severe heart
failure. The heart failure cohort comprised patients with
cardiomyopathy of various underlying causes and was of
such severity that all patients were under active consider-
ation for heart transplantation. In comparison with previous
studies examining sympathetic activity (2,11,40), the current
patient group had more severe depression of left ventricular
ejection fraction despite the continuation of antifailure ther-
apy during neurochemical assessment .
Neurochemical profile of whole body and cardiac sympa-
thetic activity . Patients with heart failure demonstrated
marked elevation of whole body and cardiac sympathetic
activity compared with levels in a control group of healthy
volunteers of comparable ages. Sympathetic activation was
reflected peripherally by elevation of arterial plasma norepi-
nephrine, which, as described previously (2,41) and con-
firmed in the current study, is due to both an increase in
the whole body spillover rate of norepinephrine and a
coexistent decrease in the norepinephrine clearance rate .
Cardiac sympathetic activation was evident in the threefold
elevation in the rate of spillover of norepinephrine to plasma .
In association with this, the cardiac spillover of both dihy-
droxyphenylalanine, the norepinephrine precursor, and the
extraneuronal norepinephrine metabolite 3-methoxy-4-
hydroxyphenylglycol was significantly elevated in those with
heart failure. The cardiac release of neuropeptide Y, which
coexists with norepinephrine in the terminals of noradrener-
gic nerves (22-24,42), was also significantly increased in the
patients with heart failure . Although previous workers dem-
onstrated an elevation of neuropeptide Y levels in arterial
plasma samples (43,44) and the myocardium (12) of patients
with heart failure, to our knowledge the current study is the
first to document increased cardiac neuropeptide Y release
in patients with heart failure .
Although the rate of cardiac norepinephrine release mea-
sured in the current heart failure cohort is consistent with
KAYE ET AL
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rates previously reported from our laboratory
(2,11), certain
more subtle differences in the nettrochernical profile of
sympathetic nervous function in our and other studies
(I 1,40) deserve consideration . Most notable among these
differences is the degree of reduction in norepinephrine
extraction across the coronary circulation . Norepinephrine
extraction, as measured by the removal of labeled norepi-
nephrine from plasma, across the heart, is predominantly
related to the activity of the uptake-1 carrier, which under
normal conditions is responsible for removing about 70% to
80% of the norepinephrine transiting the coronary circula-
tion (40,45) . Aside from uptake-I activity, the extraction of
norepinephrine is also known to be dependent on the pres-
ence of diffusion barriers, relative blood flow and the activity
of extraneuronal metabolic processes (46) . In our study,
norepinephrine extraction from plasma by the heart was
reduced by 28% compared with reductions in previous
reports of 14% (11) and 55% (40) . In contrast to the reduction
in norepinephrine extraction across the heart, and suggesting
that this was not due to faulty neuronal uptake of norepi-
nephrine, there was a significant increase in the intraneu-
ronal production of tritiated dihydroxyphenylglycol, which
is dependent on uptake- I activity in the heart (47) . Although
it has been suggested that the reduced norepinephrine re-
uptake could account for a significant proportion of the
increased rate of spillover of norepinephrine into the coro-
nary circulation of patients with heart failure (40), the 275%
increase in norepinephrine spillover in the current study is of
a substantially greater magnitude than any possible attenu-
ation of neuronal extraction and hence must reflect to a
major extent the influence of increased nerve firing.
The mechanism for the attenuation in norepinephrine
extraction in heart failure is unclear, although several poten-
tial explanations are apparent . First, myocardial interstitial
changes have been described to varying degrees in heart
failure (48); these may increase the diffusional barrier for
radiolabeled norepinephrine between the coronary circula-
tion and sympathetic nerve terminals. Second, it may be a
consequence of sympathetic activation itself . In acute stud-
ies (47) involving electrical sympathetic nerve stimulation,
the fractional extraction of tracer across the heart has been
shown to decrease, limiting its capacity to reflect true
uptake-] activity under such conditions . Such studies do
not, however, mimic the effect of chronic cardiac sympa-
thetic stimulation, as in heart failure, and it is conceivable
that chronic sympathetic overactivity might result in some
diminution of uptake-1 activity . The possibility that the
higher coronary sinus blood flow in the heart failure group
contributed to the observed reduction in tracer extraction
could not be excluded, although previous workers (49) have
suggested that the relation is significant only at the extreme
ranges of blood flow . Regardless of the state of neuronal
norepinephrine reuptake in the failing heart, the increased
spillover of dihydroxyphenylalanine, 3-methoxy-4-hydroxy-
phenylglycol and neuropeptide
Y do confirm that sympa-
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thetic nerve firing and norepinephrine synthesis and release
are increased .
InSeence ofMjay
of heart failure . In the current study,
we compared the cardiac sympathetic profile of patients with
heart failure of ischemic and nonischemic etiology because
of previous suggestions (12) that neurochemical differences
exist between these two forms of cardiomyopathy . We found
uo differences in estimates of cardiac release or synthesis of
norepinephrine or its subsequent intraneuronal or extraneu-
ronal metabolism. Additionally, extraction of tritiated nor-
epinephrine across the heart was not influenced by the
etiology of the cardiomyopathy . Bristow et al
. (12) previ-
ously examined ex vivo failing hearts of ischemic and
nonischemic etiology and found no differences in the tissue
content of myocardial catecholamines . In contrast, tissue
they obtained from nonischemic failing hearts showed a
more marked attenuation of beta-adrenoceptor density,
whereas the ischemic myocardium demonstrated a greater
degree of receptor uncoupling. Although the latter finding
may reflect the influence of chronic ischemia (50,51), it is
difficult to attribute the differences in beta-adrenoceptor
density to differing levels of cardiac sympathetic activity
when we find no demonstrable differences in norepinephrine
release. We could not, however, exclude regional variations
in sympathetic nerve activity within the myocardium .
Influtnce of medications. One major difference between
the present study and those performed previously (2,11,40)
was our continuation of antifailure therapy during neuro
lchemical testing because of the severity of the cardiac
failure . As a consequence, this study was also able to
document that sympathoexcitation is sustained despite opti-
mal heart failure therapy . Antifailure medications were
typically furosemide, an angiotensin-converting enzyme in-
hibitor, warfarin and, in most cases, digoxin . We found no
significant influence of digoxin on whole body or cardiac
sympathetic activity when comparing patients with similar
hemodynamic profiles. Previously, digoxin has been re-
ported to have a range of effects on sympathetic nervous
traffic and transmitter release . Digoxin augments barorecep-
tor sensitivity in heart failure (52-54) and may enhance
baroreceptor-induced sympathoinhibition during physical or
chemical stimulation (38) . Ferguson et al . (37,55) reported
that intravenous administration of a short-acting cardiac
glycoside, deslanoside, reduced muscle sympathetic ner-
vous activity at rest
. This effect was presumed to be a
reflection of increased baroreceptor sensitivity rather than a
Positive inotropic effect because administration of dobue
tamine did not result in sympathoinhibition . Apart from
baroreceptor-mediated effects, digoxin has been reported in
animal studies (39) to release norepinephrine from sympa-
thetic nerve terminals . In the present study, we did not
observe any apparent effect of long-term digoxin administra-
tion (at clinically relevant doses) on the spillover of norepi-
nephrine or related metabolites from the heart or on arterial
plasma norepinephrine concentrations, whole body norepi-
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nephrine spillover or norepinephrine clearance, thus sup-
porting the findings of Goldsmith et al . (56) .
Identification of possible neural reflex processes. Despite a
general consensus that sympathetic excitation occurs in
heart failure, the location of the afferent receptors and
central pathways involved in eliciting heightened sympa-
thetic activity remain controversial . In the periphery, Leim-
bach et al. (3) reported that muscle sympathetic nervous
activity was most closely related to left ventricular filling
pressure . Similarly, Ferguson et al. (57) reported a direct
relation between muscle sympathetic activity and pulmonary
artery pressures . Others (58) have suggested a link between
muscle sympathetic nervous activity and skeletal muscle
metaboreceptor activation acutely during exercise, which
may have some relevance in heart failure .
Cardiac sympathetic tone is normally regulated by a
complex interplay of afferent neural signals predominantly
arising from arterial and cardiopulmonary baroreceptors and
processed in the cardiovascular centers of the central ner-
vous system. Distension of the left atrium and pulmonary
veins has been shown to result in a positive chronotropic
response, the afferent pathway lying in the vagus with the
efferent response being mediated by cardiac sympathetic
nerves (59). Less attention, however, has been directed
toward the effects of cardiac distension on cardiac sympa-
thetic nervous activity in structures other than the sinoatrial
node. Kurz et al . (60) found that left atrial or pulmonary
venous distension with balloon catheters increased left ven-
tricular contractility and that this increase was mediated
through cardiac sympathoexcitation . In keeping with these
findings and those of the microneurographic studies, we
observed a direct correlation, although of limited strength,
between the rate of norepinephrine spillover from the failing
heart and both mean pulmonary artery pressure and pulmo-
nary capillary wedge pressure . Mechanoreceptors have been
described (61) in the pulmonary artery, although their phys-
iologic significance remains controversial . Right ventricular
pressure receptors have also been described (62) but proba-
bly play little role in cardiovascular control .
To increase our understanding of the role of the brain in
the peripheral sympathoexcitation observed in heart failure,
we performed jugular venous sampling to measure the spill-
over of norepinephrine, its precursor dihydroxyphenylala-
nine and the metabolites dihydroxyphenylglycol and 3-
methoxy-4-hydroxyphenylglycol into the internal jugular
vein to indirectly study norepinephrine synthesis and release
in the brain. The source of monoamines released into the
human cerebral circulation has been principally ascribed to
brain neurons rather than to cerebrovascular sympathetic
nerves because overflow is not reduced by ganglion block-
ade (32). This technique has previously provided evidence
of a direct relation between central norepinephrine release
and sympathetic outflow in healthy subjects (31) and is in
agreement with animal studies (27-30,63,64) that demon-
strate an excitatory influence of noradrenergic nuclei in the
brain on sympathetic nervous outflow . We found significant
JACC Vol . 23, No . 3
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increases in the spillover of the norepinephrine precursor
dihydroxyphenylalanine and the extraneuronal metabolite
3-methoxy-4-hydroxyphenylglycol from the brain in patients
with heart failure . There was also a nonsignificant increase in
the release of endogenous ihhydroxyphenylglycol in the
heart failure group . Norepinephrine spillover was not ele-
vated . The apparent discrepancy between the latter finding
and the observed increase in efflux of the related monoam-
ines probably reflect the presence of a partial diffusional
block to norepinephrine (65), whereas the other monoamines
are more lipophilic .
Conclusions . End-stage heart Lilure is characterized by a
considerable mortality rate due either to a progressive de-
cline in pump function or to sudden death, the latter usually
caused by a ventricular arrhythmia . Cardiac sympathetic
overactivity has been implicated in the genesis of ventricular
arrhythmias, and in the present study we confirmed the
presence of heightened cardiac sympathetic tone in patients
with severe heart failure independent of the etiology of their
cardiomyopathy or the presence of digoxin therapy . We
found cardiac norepinephrine spillover rates to be signifi-
cantly correlated with pulmonary artery pressures, possibly
representing an afferent stimulus for sympathetic stimula-
tion . We also found increased cerebral neuronal cato
cholamine synthesis and release in patients with heart fail-
ure. However, the fundamental links between the
hemodynamic afferent stimulus, central neural processing
and sustained elevation of peripheral sympathetic outflow
remain unclear .
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